Optimizing DMC Management in Phase III Trials

1 minute read

Published: October 14th, 2025

Navigating multi-therapeutic Phase III studies is complex. From strict blinding protocols to scheduling senior DMC members across multiple time zones, the challenges are significant. Phastar’s tailored approach ensures that every deliverable is managed efficiently, securely, and with the highest statistical rigor. 

Key highlights from our case study: 

  • Full-Spectrum DMC Management: Over 45 blinded and unblinded outputs per meeting, including demographics, disposition, safety, and ad hoc efficacy analyses. 
  • Secure Data Handling: Transitioned from problematic shared folders to compliant sFTP systems, ensuring reliable and secure data sharing. 
  • Process Optimization: Streamlined workflows, facilitated smooth team handovers, and proactively resolved data quality issues. 
  • Stakeholder Integration: Seamlessly collaborated with sponsor and vendor teams, adding value without complexity. 

Complete the form below to read the full case study

Related articles

Translating Real-World Data into Commercial Success with Outcome Modelling 

Translating Real-World Data into Commercial Success with Outcome Modelling 

July 13th, 2026 1 minute read

Demonstrating real-world value is critical for securing pricing and market access, but bridging the gap between clini...

Scaling Real-World Evidence to Maximize Drug Lifecycle Value 

Scaling Real-World Evidence to Maximize Drug Lifecycle Value 

July 13th, 2026 1 minute read

Biopharma organizations have access to vast amounts of real-world data, but extracting meaningful, actionable insight...

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer

Extending Trial Value with Long-Term Benefit–Risk Simulation in Prostate Cancer

July 13th, 2026 1 minute read

Demonstrating short-term efficacy is no longer enough, regulators increasingly require a clear understanding of long-...